The LOTUS study reported that ipatasertib in combination with paclitaxel improved PFS in patients with PIK3CA/Akt1/PTEN-altered TNBC, suggesting that PIK3CA/Akt1/PTEN alterations can also be biomarkers of response to ipatasertib in patients with breast cancer [18]. This evidence concerns the gene AKT1 and breast carcinoma.